# Clostridioides difficile Treatment Selection

Select therapy after confirming clinically compatible toxin-mediated disease, classify nonfulminant versus fulminant illness, favor fidaxomicin when feasible, use vancomycin when access or severity dictates, and add recurrence-prevention strategies for patients with prior episodes or high-risk features.

**Clinical question:** How should clinicians select antimicrobial and recurrence-prevention therapy for initial, recurrent, and fulminant Clostridioides difficile infection?

Updated: 2026-09-15T22:10:58.519135+00:00

## What matters in practice
- For an initial nonfulminant CDI episode, IDSA/SHEA conditionally prefers fidaxomicin over vancomycin because it improves sustained response through lower recurrence; vancomycin remains an acceptable alternative when resources limit fidaxomicin use.[17][20]
- Use oral or nasogastric vancomycin 500 mg four times daily—not fidaxomicin—for fulminant CDI; add intravenous metronidazole 500 mg every 8 hours and consider rectal vancomycin when ileus impairs colonic drug delivery.[17][18]
- For a first recurrence, fidaxomicin is preferred when feasible; vancomycin taper-and-pulse remains a practical alternative, particularly for patients with multiple recurrences.[17]
- After at least two recurrences, move beyond repeated standard antibiotic courses: use an antibiotic regimen followed by microbiota restoration, including conventional FMT or FDA-approved fecal microbiota-based therapies where available.[13][15][18]
- Treat a positive assay only in the appropriate clinical context: NAAT-positive/toxin-EIA-negative results can represent toxigenic carriage and require clinical adjudication rather than automatic therapy.[4]

## Confirm CDI and identify fulminant disease before choosing therapy

Treatment selection depends on clinical disease, assay interpretation, and immediate severity assessment.

Test and treat patients with clinically compatible diarrheal illness rather than a positive molecular result alone. CDI requires compatible manifestations plus stool evidence of a toxigenic strain and toxin activity; NAAT detects toxin genes, whereas toxin enzyme immunoassay (EIA) detects stool toxin. Multistep algorithms using GDH and toxin EIA, arbitrated by NAAT, improve interpretation over a standalone assay.[3][4][24]

A NAAT-positive or GDH-positive/toxin-EIA-negative result is indeterminate for treatment selection: it may reflect low-level toxin below EIA detection in true CDI or asymptomatic toxigenic carriage. A third-stage NAAT, GDH, or toxigenic culture can address an apparent false-positive screening result but does not distinguish carriage from active CDI; reassess stool frequency, competing causes of diarrhea, systemic findings, and trajectory before prescribing CDI-directed antibiotics.[4]

Classify nonsevere disease using WBC no greater than 15,000 cells/mL and serum creatinine below 1.5 mg/dL. Fulminant CDI is defined by hypotension or shock, ileus, or megacolon and requires immediate high-dose vancomycin-based therapy rather than the usual fidaxomicin-versus-vancomycin selection pathway.[2][17]
- Stop the implicated antibacterial agent when clinically safe; this is a core early intervention alongside CDI-directed treatment.[1]
- Hospitalize patients with systemic symptoms or organ dysfunction; outpatient treatment is reserved for patients without either feature.[1]
- Do not use a toxin-negative molecular result as an automatic mandate to treat; document the clinical rationale if treatment is chosen despite discordance.[4]

*Diagnostic and severity findings that change the immediate CDI treatment pathway.[2][4][17]*

| Finding | Interpretation | Treatment consequence |
| --- | --- | --- |
| NAAT positive or GDH positive plus toxin EIA positive | Supports toxin-mediated CDI in a symptomatic patient.[4] | Select therapy by episode number and severity.[17] |
| NAAT positive or GDH positive plus toxin EIA negative | Could be active CDI with toxin below detection or toxigenic carriage.[4] | Reassess clinical probability and alternative diarrhea etiologies before treatment.[4] |
| WBC ≤15,000 cells/mL and creatinine <1.5 mg/dL | Laboratory pattern supporting nonsevere disease.[2] | Use a standard nonfulminant regimen.[2][17] |
| Hypotension, shock, ileus, or megacolon | Fulminant CDI.[17] | Begin high-dose oral or NG vancomycin plus IV metronidazole; add rectal vancomycin for ileus.[17][18] |

## Choose fidaxomicin or vancomycin for initial nonfulminant CDI

For nonfulminant disease, recurrence prevention drives first-line agent selection.

For an initial nonfulminant episode, select oral fidaxomicin when available and affordable because IDSA/SHEA conditionally prefers it over vancomycin based on improved sustained clinical response. The advantage is reduced recurrence, not a demonstrated difference in initial cure, mortality, or adverse events; therefore oral vancomycin is an appropriate alternative when access, coverage, discharge logistics, or formulary restrictions preclude fidaxomicin.[17][20]

Use a 10-day course of fidaxomicin or oral vancomycin for initial nonfulminant CDI. Metronidazole is no longer preferred and should be reserved for settings in which fidaxomicin and vancomycin are unavailable.[2][7][17]

Give particular weight to sustained response when recurrence would carry disproportionate consequences, such as a prior CDI history or a patient in whom further microbiome disruption would be especially consequential. Recurrence after an initial episode occurs in up to 25% of patients within 2 to 8 weeks after antibiotic treatment, and recurrence probability rises after each episode.[7]
- Fidaxomicin: preferred IDSA/SHEA option for initial nonfulminant CDI when resources permit.[17]
- Oral vancomycin: acceptable initial nonfulminant alternative; use it when fidaxomicin is not feasible.[17][20]
- Metronidazole: use only when first-line agents cannot be accessed.[2]

*Initial nonfulminant CDI regimen selection.[2][17][20]*

| Option | When to select | Key tradeoff |
| --- | --- | --- |
| Fidaxomicin for 10 days | Preferred for initial nonfulminant CDI when available.[2][17] | Higher sustained response through lower recurrence; cost and access can limit use.[17][20] |
| Oral vancomycin for 10 days | Use when fidaxomicin is unavailable, unaffordable, or impractical.[2][17] | Acceptable initial clinical response but less favorable recurrence outcome than fidaxomicin.[17][20] |
| Metronidazole | Reserve for limited-access settings where fidaxomicin and vancomycin are unavailable.[2] | Deprioritized because first-line alternatives are preferred.[2][7] |

## Treat fulminant CDI with high-dose vancomycin-based combination therapy

Do not extrapolate fidaxomicin recommendations to hypotension, shock, ileus, or megacolon.

For fulminant CDI, administer vancomycin 500 mg orally or by nasogastric tube four times daily and add intravenous metronidazole 500 mg every 8 hours. IDSA/SHEA continues to recommend vancomycin rather than fidaxomicin in this setting because fulminant disease was excluded from the trials supporting fidaxomicin.[17][18]

If ileus is present, add rectal vancomycin retention enemas every 6 hours because oral or nasogastric delivery may not reliably reach the colon. Manage fulminant disease in a setting capable of intensive monitoring, and obtain early surgical consultation while medical therapy is initiated because fulminant CDI can progress rapidly.[13][18]

The immediate objective is not recurrence optimization but restoration of perfusion, colonic drug exposure, and control of systemic toxicity. Reassess hemodynamics, abdominal examination, ileus, and evidence of megacolon serially; persistent deterioration despite appropriate combination therapy should trigger urgent escalation rather than substitution with routine nonfulminant regimens.[17][18]
- Vancomycin 500 mg PO or NG four times daily is the IDSA/SHEA fulminant regimen.[17]
- Add metronidazole 500 mg IV every 8 hours.[18]
- With ileus, add rectal vancomycin every 6 hours as retention enemas.[18]
- Seek surgical input early in fulminant CDI while continuing antimicrobial therapy.[13][18]

*Fulminant CDI regimen and delivery modifications.[17][18]*

| Clinical circumstance | CDI-directed treatment | Operational action |
| --- | --- | --- |
| Fulminant CDI without ileus | Vancomycin 500 mg PO or NG four times daily plus metronidazole 500 mg IV every 8 hours.[17][18] | Monitor in a high-acuity setting and involve surgery early.[13][18] |
| Fulminant CDI with ileus | Add rectal vancomycin retention enemas every 6 hours to oral or NG vancomycin plus IV metronidazole.[18] | Do not rely on enteral delivery alone when ileus may limit colonic exposure.[18] |

## Escalate therapy after recurrence rather than repeating the same short course

Episode number and recurrence risk determine whether to use antibiotics alone, adjunctive antibody, or microbiota restoration.

For a first recurrence, prefer fidaxomicin over a standard vancomycin course when feasible. Vancomycin remains effective for initial clinical cure, and an extended tapered-and-pulsed vancomycin regimen is an accepted alternative, especially where fidaxomicin access is constrained or in patients with multiple recurrences.[17][20]

Consider a single intravenous dose of bezlotoxumab as adjunctive recurrence prevention in patients with a CDI recurrence within the prior 6 months. It is a monoclonal antibody against toxin B and is used with—not instead of—an active CDI antibiotic regimen; select it for patients in whom preventing another episode has high clinical value.[13][18]

For second or subsequent recurrence, avoid cycling indefinitely through standard 10-day antibiotic courses. Options include fidaxomicin, tapered-and-pulsed vancomycin, or vancomycin followed by rifaximin 400 mg orally every 8 hours for 20 days; after appropriate antibiotic treatment for at least two recurrences, proceed to fecal microbiota transplantation or another microbiota-based recurrence-prevention strategy.[18]
- First recurrence: fidaxomicin is preferred when feasible; tapered-and-pulsed vancomycin is an accepted alternative.[17]
- Recurrence within 6 months: consider adjunctive single-dose IV bezlotoxumab.[18]
- Second or subsequent recurrence: plan microbiota restoration after antibiotic treatment rather than relying solely on repeated standard courses.[13][18]
- FDA-approved fecal microbiota-based products, including fecal microbiota live-jslm and fecal microbiota spores live-brpk, are additional U.S. recurrence-prevention options.[15]

### Selecting microbiota restoration

Conventional FMT has high reported effectiveness in multiply recurrent CDI, with one expert review citing success greater than 85% compared with 40% to 50% for antibiotics in that setting. Current U.S. practice also includes FDA-approved fecal microbiota-based therapies, expanding options beyond conventional donor-stool FMT.[13][15]
- Use microbiota restoration after antibiotic treatment for recurrent CDI, not as a substitute for acute control of fulminant disease.[13][18]
- Choose between conventional FMT and available FDA-approved microbiota-based products according to local expertise, product access, route, and patient-specific risk assessment.[1][15]

*Episode-based selection for recurrent CDI.[13][17][18]*

| Episode pattern | Preferred or accepted treatment options | Prevention escalation |
| --- | --- | --- |
| First recurrence | Fidaxomicin preferred; tapered-and-pulsed vancomycin is an alternative.[17] | Consider single-dose IV bezlotoxumab when recurrence occurred within 6 months.[18] |
| Second or subsequent recurrence | Fidaxomicin, tapered-and-pulsed vancomycin, or vancomycin followed by rifaximin 400 mg PO every 8 hours for 20 days.[18] | After appropriate antibiotics for at least two recurrences, use FMT or another microbiota restoration strategy.[13][18] |
| Multiply recurrent CDI | Treat the active episode with an effective CDI antibiotic regimen.[13][18] | Prioritize microbiota restoration; FMT success has been reported at greater than 85% in this setting.[13] |

## Use treatment response and recurrence timing to guide follow-up

The therapeutic endpoint is sustained clinical response, not simply completion of an antibiotic prescription.

At treatment initiation, discontinue the inciting antimicrobial when possible and review ongoing acid-suppressive therapy because antibiotic stewardship and discontinuation of chronic acid suppression are identified prevention and management measures. When the non-CDI antibacterial cannot be stopped, document the indication and narrow or shorten it whenever clinically safe.[1][16]

Assess clinical response during therapy by stool frequency, systemic status, volume needs, abdominal findings, WBC, and creatinine rather than using repeat stool assays as a surrogate for cure. For initial and recurrent nonfulminant disease, the key comparative endpoint favoring fidaxomicin is sustained response at 4 weeks for initial CDI and at 30 days in recurrent CDI; cure, mortality, and adverse-event rates were comparable with vancomycin in pooled analyses.[20]

A return of compatible diarrhea 2 to 8 weeks after therapy should prompt reassessment for recurrence, because this is the usual reported recurrence window after an initial treated episode. Repeat multistep testing only in a patient with recurrent symptoms compatible with CDI; then select therapy according to whether this is the first versus subsequent recurrence and whether the patient has progressed to fulminant illness.[7][24]
- Stop or narrow non-CDI antibacterials whenever clinically safe.[1]
- Review chronic acid suppression as a modifiable management factor.[16]
- For recurrent compatible symptoms, re-enter the diagnostic and severity pathway rather than empirically repeating a prior regimen.[4][17]

*Follow-up actions that change subsequent CDI treatment decisions.[7][17][20]*

| Follow-up finding | Interpretation | Next action |
| --- | --- | --- |
| Clinical improvement during treatment | Supports active response; sustained response is the relevant longer-term endpoint.[20] | Complete the selected regimen and minimize modifiable recurrence drivers.[1][16] |
| Compatible diarrhea returns 2-8 weeks after treatment | Consistent with the reported post-treatment recurrence window.[7] | Reassess with a multistep diagnostic approach and classify as first or subsequent recurrence.[4][17] |
| Hypotension, shock, ileus, or megacolon develops at any episode number | Signals fulminant CDI rather than routine recurrence management.[17] | Switch immediately to high-dose vancomycin plus IV metronidazole; add rectal vancomycin if ileus is present.[17][18] |

## References
1. Clostridioides difficile-associated disease - Management Approach | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/230/management-approach
2. Clostridioides difficile-associated disease - Treatment algorithm | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/230/treatment-algorithm
3. Discordant Clostridioides difficile diagnostic assay and treatment ... — bmjopen.bmj.com — https://bmjopen.bmj.com/content/bmjopen/10/9/e036342.full.pdf
4. Discordant Clostridioides difficile diagnostic assay and treatment practice: a cross-sectional study in a tertiary care hospital, Geneva, Switzerland | BMJ Open — bmjopen.bmj.com — https://bmjopen.bmj.com/content/10/9/e036342
5. Discordant Clostridioides difficile diagnostic assay and ... - BMJ Open — bmjopen.bmj.com — https://bmjopen.bmj.com/content/10/9/e036342.reviewer-comments
6. Effective treatment of Clostridioides difficile infection improves survival and affects graft-versus-host disease: a multicenter study by the Polish Adult Leukemia Group | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-024-56336-3
7. Experimental glycopeptide antibiotic EVG7 prevents recurrent Clostridioides difficile infection by sparing members of the Lachnospiraceae family | Nature Communications — www.nature.com — https://www.nature.com/articles/s41467-025-64067-w
8. Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Clostridioides difficile infection - An observational cohort study — www.cell.com — https://www.cell.com/heliyon/fulltext/S2405-8440(24)06773-2
9. Experimental human colonisation with non-toxigenic Clostridioides difficile: a placebo-controlled randomised clinical trial | Nature Communications — www.nature.com — https://www.nature.com/articles/s41467-026-74327-y
10. Plasmid-mediated metronidazole resistance in Clostridioides difficile | Nature Communications — www.nature.com — https://www.nature.com/articles/s41467-020-14382-1
11. Retrospective Assessment of Guideline Adherence and Treatment Outcomes From Clostridioides difficile Infection Following the IDSA 2021 Clinical Guideline Update: Clostridioides difficile Infection | Open Forum Infectious Diseases | Oxford Academic — academic.oup.com — https://academic.oup.com/ofid/article/11/10/ofae524/7758543
12. Consumption and expenditure on fidaxomicin and oral vancomycin for Clostridioides difficile infection: A 12-year longitudinal study of 43 countries and regions - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0924857925002195
13. My Treatment Approach to Clostridioides difficile Infection — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0025619621002639
14. Approach to Clostridioides difficile diarrheal infection - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2950590925000204
15. Clinician Management Preferences for Clostridioides difficile Infection in Adults: A 2024 Emerging Infections Network Survey | Open Forum Infectious Diseases | Oxford Academic — academic.oup.com — https://academic.oup.com/ofid/article/12/7/ofaf335/8165984
16. Review Management of Clostridioides difficile Infection: Diagnosis ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0002934324001670
17. SHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection in Adults — www.idsociety.org — https://www.idsociety.org/practice-guideline/clostridioides-difficile-2021-focused-update#idsa-main-nav
18. Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780550
19. Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36441203&dopt=Abstract
20. Navigating the 2021 update to the IDSA/SHEA Clostridioides difficile guidelines: An ethical approach to equitable patient care - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726573
21. AGA Clinical Practice Guideline on Fecal Microbiota-Based ... — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(24)00041-6/pdf
22. [PDF] Advice on the designation of antimicrobials or groups of — www.ema.europa.eu — https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/advice-designation-antimicrobials-or-groups-antimicrobials-reserved-treatment-certain-infections-humans-relation-implementing-measures-under-article-375-regulation-eu-20196-veterinary-medicinal_en.pdf
23. AGA Clinical Practice Update on Management of Clostridioides ... — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(26)00245-3/abstract
24. Clostridioides difficile Infection in Children: Recent Updates on ... — publications.aap.org — https://publications.aap.org/pediatrics/article/152/3/e2023062307/193288/Clostridioides-difficile-Infection-in-Children

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.